AN OVERVIEW OF COLORECTAL CANCER: IMPLICATION OF TWO MEDICINAL PLANTS IN THEIR TREATMENT
Nowadays, cancer is one of the most common diseases in humans. Among all types, colorectal cancer (CRC) is one of the most serious types diagnosed in men after lung and prostate cancer while in women it occupies the second position after breast cancer worldwide. The risk factors such as obesity, sedentary lifestyle, bad nutritional habits (high in fats and proteins), smoking, and progressive aging are the cause of CRC. The acquisition of abnormal mutations leads to a consisting of many different arrangements of events during the tumor development process. Over the years, different approaches have been employed, in the treatment of cancer. These include chemotherapy, radiotherapy, surgery, and immunotherapy. Chemotherapy is routinely used for cancer treatment, but the toxicity of chemotherapeutics on healthy cells of the human body is obvious. This is the reason for discovering the new, natural origin, substances with potential cytostatic effects and less toxic side effects on the healthy cells. Medicinal plants have a special place in the management of cancer. Numerous cancer research studies have been conducted using traditional medicinal plants to discover new therapeutic agents with fewer side effects. In this review, we are describing two medicinal plants such as Actiniopteris radiata (Sw.) Link (Mayurashikha) and Terminalia pallida Brandis (Tella karaka) (endemic plant) which are available immensely in Chittoor District are used till today by the traditional herbal practitioners, tribal people is near to Talakona forest and Ayurvedic people for various diseases and also for CRC.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45.
3. Alam MN, Almoyad M, Huq F. Polyphenols in colorectal cancer: Current state of knowledge including clinical trials and molecular mechanism of action. Biomed Res Int 2018;2018:4154185.
4. DeVita V, Lawrence T, Rosenberg S. Cancer: Principles and Practice of Oncol. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2011.
5. Calva AM, Acevedo Tirado MT, Revision Y. Actualization general en cancer colorectal. Rev Radiol Mexico 2009;1:99-115.
6. Potter JD. Colorectal cancer: Molecules and populations. J Natl Cancer Instit 1999;91:916-32.
7. Terzi? J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14.
8. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166-75.
9. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control 2013;24:1207-22.
10. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B, et al. Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-99.
11. Ponz de Leon M, Benatti P, Borghi F, Pedroni M, Scarselli A, Di Gregorio C, et al. Aetiology of colorectal cancer and relevance of monogenic inheritance. Gut 2004;53:115-22.
12. Ahsan H, Neugut AI, Garbowski GC, Jacobson JS, Forde KA, Treat MR. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998;128:900-5.
13. Bonelli L, Martines H, Conio M, Bruzzi P, Aste H. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988;41:513-7.
14. Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004;41:801-7.
15. Hemminki K, Chen B. Familial risk for colorectal cancers are mainly due to heritable causes. Cancer Epidemiol Biomarkers Prev 2004;13:1253-6.
16. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: A quantitative overview of the epidemiological evidence. Int J Cancer 2009;125:171-80.
17. Watson AJ, Collins PD. Colon cancer: A civilization disorder. Dig Dis 2011;29:222-8.
18. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21:433-40.
19. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001;96:2992-3003.
20. Silva AC, Hara AK, Leighton JA, Heppell JP. CT colonography with intravenous contrast material: Varied appearances of colorectal carcinoma. Radiographics 2005;25:1321-34.
21. Granados-Romero JJ, Valderrama-Trevino AI, Contreras-Flores EH, Barrera-Mera B, Enriquez MH, Uriarte-Ruiz K, et al. Colorectal cancer: A review. Int J Res Med Sci 2017;5:4667-76.
22. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
23. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-62.
24. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
25. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45.
26. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of cpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008;3:e3698.
27. Kato K, Matsuda M, Ingu A, Imai M, Kasai S, Mito M. Colon cancer with a high serum alpha-fetoprotein level. Am J Gastroenterol 1996;91:1045-6.
28. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. P53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87:7555-9.
29. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both DPC4 (Smad4) and APC genes. Cell 1998;92:645-56.
30. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, et al. P27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7:51-63.
31. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005;5:184-98.
32. National Comprehensive Cancer Network Guidelines (NCCN Guidelines). Colorectal Cancer Screening. Washington: NCCN Guidelines; 2014.
33. Jeffery M, Hickey BE, Hider PN. The Cochrane Database of Systematic Reviews. Hoboken, N.J.: John Wiley & Sons, Ltd.; 1996.
34. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: The FACS randomized clinical trial. JAMA 2014;311:263-70.
35. Martin-Perez B, Andrade-Ribeiro GD, Hunter L, Atallah S. A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013. Tech Coloproctol 2014;18:775-88.
36. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH; Pathology Review Committee. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350-7.
37. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009;373:821-8.
38. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery – the clue to pelvic recurrence? Br J Surg 1982;69:613-6.
39. Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014;20:10316-30.
40. Al-Keilani MS, Alsmadi DH. The HDAC inhibitor sodium phenylbutyrate enhances the cytotoxicity by 5-fluorouracil, oxaliplatin, and irinotecan in colorectal cancer cell lines. Int J Pharm Pharm Sci 2018;10:155-9.
41. Mutiah R, Sukardiman, Widyawaruyanti A. Cytotoxic effect of crude extract and fraction from Calotropis gigantea leaves on human colon cancer widr cell lines. Int J Pharm Pharm Sci 2017;9:83-6.
42. Rafieian-Kopaie M, Nasri H. On the occasion of world cancer day 2015; the possibility of cancer prevention or treatment with antioxidants: The ongoing cancer prevention researches. Int J Prev Med 2015;6:108.
43. Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S264-72.
44. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77.
45. Mansouri E, Kooti W, Bazvand M, Ghasemi Boroon M, Amirzargar A, Afrisham R, et al. The effect of hydro-alcoholic extract of Foeniculum vulgare mill on leukocytes and hematological tests in male rats. Jundishapur J Nat Pharm Prod 2015;10:e18396.
46. Kooti W, Ghasemiboroon M, Asadi-Samani M, Ahangarpoor A, Ahmad Abadi MN, Afrisham R, et al. The effects of hydro-alcoholic extract of celery on the lipid profile of rats fed a high-fat diet. Adv Environ Biol 2014;8:325-30.
47. Kooti W, Hasanzadeh-Noohi Z, Sharafi-Ahvazi N, Asadi-Samani M, Ashtary-Larky D. Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin J Nat Med 2016;14:732-45.
48. Sakarkar DM, Deshmukh VN. Ethnopharmacological review of traditional medicinal plants for anticancer activity. Int J Pharm Tech Res 2011;3:298-308.
49. Kooti W, Servatyari K, Behzadifar M, Asadi-Samani M, Sadeghi F, Nouri B, et al. Effective medicinal plant in cancer treatment, part 2: Review study. J Evid Based Complementary Altern Med 2017;22:982-95.
50. Porte SM. Overview of folk medicine used for Typhoid in India. Int J Res Ayurveda Pharm 2014;5:219-24.
51. Pingale Shirish S, Deokar Dinesh E, Punde Vikas M. Recent developments in Actiniopteris radiata. Int Res J Sci Eng 2018;A3:165-72.
52. Singh S, Singh R. Ethnomedicinal use of pteridophytes in reproductive health of tribal women of pachmarhi biosphere reserve, Madhya Pradesh, India. Int J Pharm Sci Res 2012;3:4780-90.
53. Gupta RS, Sharma R. Review on medicinal plant exhibiting antifertility activity in male. Natl Prod Radiance 2006;5:389-410.
54. Singh S, Singh R. Utilization of pteridophyte of Achanakmar- Amarckantak biosphere reserve, central India in women’s health and beauty care practices. Int Res J Pharm 2013;4:235-40.
55. Nyarko HD, Victor YA, Batama BJ. Antimicrobial examinations of Cymbopogon citratus and Adiatum capillusveneris used in Ghanaian folkloric medicine. Int J Life Sci Res 2012;2:L115-8.
56. Santhosh Kumar S, Samydurai P, Nagarajan N. Indigenous knowledge on some medicinal pteridophytic plant species among the Malasar Tribe’s in Valparai Hills, Western Ghats of Tamil Nadu. Am J Ethnomed 2014;1:164-73.
57. Revathi R, Muthuraja R, Thomas B, Raju K. Ethnomedicinal fern and fern-allies used by tribe Malayalis of Kolli Hills, Eastern Ghats, Tamil Nadu. Pteridol Res 2013;2:1-10.
58. Hemalatha K, Sunandana Rao N, Shivaji N. Phytochemical constituents of Actiniopteris radiata Linn. Whole plant. Ann Phytomed Int J 2012;1:34-8.
59. Narasimhaiah L, Chandrasekhar MJ, Alexander S. Isolation of new glycosides from pteridophyte plant. Int J Pharm Pharm Sci 2012;4:615-7.
60. Rajesh KD, Vasantha S, Rajesh NV, Panneerselvam A. Qualitative and quantitative phytochemical analysis in four pteridophytes. Int J Pharm Sci Rev Res 2014;27:408-12.
61. Ramalingeswara Reddy P, Sreenivasulu M, Chand Basha S. Actiniopteris radiata (linn.): A comprehensive review. J Global Trends Pharm Sci 2012;3:612-8.
62. Alai VR, Vadnere GP. In vitro Antihistaminic and anticholinergic activity of Actiniopteris radiata (Sw.) Link. on isolated rat ileum. Int J Pharmtech Res 2011;3:5-7.
63. Dixit SK, Bhatt GK. Folk-lore studies on unknown indigenous antifertility drugs. J Res Ind Med 1975;10:77-81.
64. Munna S, Chand Basha S, Ramalingewara Reddy P, Pramod N, Pradeep Kumar Y, Mahaboob Basha G. The antitubercular activity of Actiniopteris radiata Linn. J Global Trends Pharm Sci 2014;5:1443-5.
65. Moorthy D, Paulsamy S, Nandha Kumar K, Saradha M. In vitro antibacterial activity of the fern, Actiniopteris radiata (Sw.) Link. inhabiting the Shervaroyan Hills, the Eastern Ghats. J Chem Pharm Res 2013;5:211-4.
66. Sreenivasulu V, Chand Basha S, Adinarayan Y, Lingaswam V, Praveen Kumar UN. Anthelmintic activity of Actiniopteris radiata (linn.). J Global Trends Pharm Sci 2014;5:1716-8.
67. Naik JB, Jadege DR. Antibacterial and antifungal activity of Actiniopteris radiata (Sw.) Link. International Journal of PharmTech Research 2010;2:1751-3.
68. Vadnere GP, Pathan AR, Songhai AK, Kulkarni BU, Hundiwale JC. Anti-stress and anti-allergic effect of Actiniopteris radiata in some aspects of asthma. Pak J Pharm Sci 2013;26:195-8.
69. Manjunath M, Lavanya G, Sivajyothi R, Reddy OV. Antioxidant and radical scavenging activity of Actiniopteris radiata (Sw.) link. Asian J Exp Sci 2011;25:73-80.
70. Paulsamy S, Moorthy D, Nandakumar K, Saradha M. Evaluation of in vitro antioxidant potential of methanolic extracts of the ferns, Actiniopteris radiata (sw) link. and Equisetum ramosissimum desf. Int J Res Dev Pharm Life Sci 2013;3:451-5.
71. Naga Sravanthi K, Rajeshwara Rao P, Niranjan J. Hepatoprotective activity of ethanolic extract of Actiniopetris radiata Linn against ccl4 induced hepatotoxicity in Wistar albino rats. Int J Res Pharmacol Pharmacother 2012;1:201.
72. Naik B, Jadge DR, Deshpande AN, Gadgul AB, Siddiqui AR. Pharmacological and phytochemical review on Actiniopteris radiata. Int J Pharm Sci Res 2017;4:1373-7.
73. Solomon Raju AJ, Vara Lakshmi P, Venkata Ramana K. Department of Environmental Sciences. Andhra University, Visakhapatnam, India; 2019.
74. Chattopadhyay RR, Bhattacharyya SK. Terminalia chebula: An update. Pharmacogn Rev 2007;1:151-6.
75. Shaik HA, Eswaraih MC, Lahari M, Maruthi Rao B, Ali SF. Evaluation of analgesic and anti-pyretic activities of ethanolic extract of Terminalia pallida (EETP) stem in experimental animals. Sch J Appl Med Sci 2013;1:5-8.
76. Kameswara Rao B, Renuka Sudarshan P, Rajasekhar MD, Nagaraju N, Appa Rao C. Antidiabetic activity of Terminalia pallida fruit in alloxan induced diabetic rats. J Ethnopharmacol 2003;85:169-72.
77. Sampathkumar MT, Kasetti RB, Nabi SA, Sudarshan PR, Swapna S, Apparao C. Antihyperlipidemic and antiatherogenic activities of Terminalia pallida linn. Fruits in high fat diet-induced hyperlipidemic rats. J Pharm Bioallied Sci 2011;3:449-52.
78. Palani S, Raja S, Venkadesan D, Karthi S, Sakthivel K, Senthil Kumar B. Antioxidant activity and hepatoprotective potential of Terminalia pallida. Arch Appl Sci Res 2009;1:18-28.
79. Gupta M, Mazumder UK, Manikandan L, Bhattacharya S, Senthilkumar GP, Suresh R, et al. Anti-ulcer activity of ethanol extract of Terminalia pallida brandis. in swiss albino rats. J Ethnopharmacol 2005;97:405-8.
80. Gupta M, Mazumder UK, Manikandan L, Bhattacharya S, Haldar PK, Roy S, et al. Antibacterial activity of Terminalia pallida. Fitoterapia 2002;73:165-7.
81. Rajasekhar K, Reddy R, Raju V. Phytochemical evaluation and antimicrobial studies on Terminalia pallida Brandis (Combretaceae) – A rare and endemic medicinal plant. Int J Pharm Res Dev 2013;5:40-4.
82. Hashemzaei M, Barani AK, Iranshahi M, Rezaee R, Tsarouhas K, Tsatsakis AM, et al. Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats. Environ Toxicol Pharmacol 2016;46:110-5.
83. Hashemzaei M, Entezari Heravi R, Rezaee R, Roohbakhsh A, Karimi G. Regulation of autophagy by some natural products as a potential therapeutic strategy for cardiovascular disorders. Eur J Pharmacol 2017;802:44-51.
84. Hashemzaei M, Sadeghi Bonjar MA, Tabrizian K, Iranshahi M, Iranshahy M, Rezaee R. Evaluation of the analgesic effect of Umbelliprenin and Umbelliprenin-morphine co-administration on the acute, chronic and neuropathic pain. Indian J Pharm Educ Res 2015;49:121-5.
85. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal 2013;2013:162750.
86. Tabrizian K, Yaghoobi NS, Iranshahi M, Shahraki J, Rezaee R, Hashemzaei M. Auraptene consolidates memory, reverses scopolamine-disrupted memory in passive avoidance task, and ameliorates retention deficits in mice. Iran J Basic Med Sci 2015;18:1014-9.
87. Nikitovic D, Tsatsakis AM, Karamanos NK, Tzanakakis GN. The effects of genistein on the synthesis and distribution of glycosaminoglycans/ proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res 2003;23:459-64.
88. Yamaguchi M, Murata T, El-Rayes BF, Shoji M. The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA paCa-2 cells in vitro: Comparison with gemcitabine. Oncol Rep 2015;34:3304-10.
89. Cárdenas M, Marder M, Blank VC, Roguin LP. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg Med Chem 2006;14:2966-71.
90. Chan FL, Choi HL, Chen ZY, Chan PS, Huang Y. Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin. Cancer Lett 2000;160:219-28.
91. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem 1999;63:896-9.
92. Lin P, Tian XH, Yi YS, Jiang WS, Zhou YJ, Cheng WJ. Luteolin-induced protection of H2O2-induced apoptosis in PC12 cells and the associated pathway. Mol Med Rep 2015;12:7699-704.
93. Leung HW, Kuo CL, Yang WH, Lin CH, Lee HZ. Antioxidant enzymes activity involvement in luteolin-induced human lung squamous carcinoma CH27 cell apoptosis. Eur J Pharmacol 2006;534:12-8.
94. Wu TH, Yen FL, Lin LT, Tsai TR, Lin CC, Cham TM, et al. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008;346:160-8.
95. Busch C, Burkard M, Leischner C, Lauer UM, Frank J, Venturelli S. Epigenetic activities of flavonoids in the prevention and treatment of cancer. Clin Epigenetics 2015;7:64.
96. Gilbert ER, Liu D. Flavonoids influence epigenetic-modifying enzyme activity: Structure – Function relationships and the therapeutic potential for cancer. Curr Med Chem 2010;17:1756-68.
97. Deng XH, Song HY, Zhou YF, Yuan GY, Zheng FJ. Effects of quercetin on the proliferation of breast cancer cells and expression of survivin in vitro. Exp Ther Med 2013;6:1155-8.
98. Ren KW, Li YH, Wu G, Ren JZ, Lu HB, Li ZM, et al. Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells. Int J Oncol 2017;50:1299 311.
99. Chen J, Kang JH. Quercetin and trichostatin A cooperatively kill human leukemia cells. Pharmazie 2005;60:856-60.
100. Priego S, Feddi F, Ferrer P, Mena S, Benlloch M, Ortega A, et al. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: A Bcl-2- and superoxide dismutase 2-dependent mechanism. Mol Cancer Ther 2008;7:3330 42.
101. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994;34:459-64.
102. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, et al. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 1990;260:10-3.
103. Sharma H, Sen S, Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 2005;4:949-55.
104. Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos 2006;34:296-304.
105. Gao X, Wang B, Wei X, Men K, Zheng F, Zhou Y, et al. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale 2012;4:7021-30.
106. Cao HH, Tse AK, Kwan HY, Yu H, Cheng CY, Su T, et al. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol 2014;87:424-34.
107. Spagnuolo C, Russo M, Bilotto S, Tedesco I, Laratta B, Russo GL. Dietary polyphenols in cancer prevention: The example of the flavonoid quercetin in leukemia. Ann N Y Acad Sci 2012;1259:95 103.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.